[Chemosensitivity test for unresectable non-small cell lung cancer]

Area of Science:

• Oncology
• Cancer Research
• Drug Discovery

Context:

• Non-small cell lung cancer (NSCLC) presents significant treatment challenges.
• Optimal chemotherapy regimen selection is crucial for patient outcomes.
• Current chemosensitivity tests often require substantial cell quantities.

Purpose:

• To evaluate the efficacy of the collagen gel droplet embedded culture drug sensitivity test (CDDST) for non-small cell lung cancer (NSCLC).
• To assess the CDDST's accuracy in predicting in vitro and in vivo chemotherapy responses.
• To determine if CDDST-guided chemotherapy improves survival in unresectable NSCLC.

Summary:

• The CDDST is a novel chemosensitivity assay requiring minimal cancer cells, suitable for NSCLC and malignant effusions.
• The test demonstrated high accuracy with a 75.0% true positive and 85.0% true negative ratio.
• Patients receiving CDDST-guided optimal chemotherapy showed a significantly longer median survival time (15.8 months) compared to those who did not (5.6 months).

Impact:

• The CDDST offers a reliable and efficient method for personalized chemotherapy selection in NSCLC.
• This approach has the potential to enhance treatment efficacy and patient survival in unresectable NSCLC.
• The study validates CDDST as a valuable tool in clinical oncology decision-making for lung cancer patients.